Generic Amyvid Availability
Last updated on May 7, 2025.
Amyvid is a brand name of florbetapir F 18, approved by the FDA in the following formulation(s):
AMYVID (florbetapir f-18 - solution;intravenous)
-
Manufacturer: AVID RADIOPHARMS INC
Approval date: April 6, 2012
Strength(s): 10ML (13.5-51mCi/ML) (discontinued) [RLD], 10-30ML (13.5-51mCi/ML) (discontinued) [RLD], 10-50ML (13.5-51mCi/ML) [RLD] -
Manufacturer: AVID RADIOPHARMS INC
Approval date: October 13, 2023
Strength(s): 10-100ML (13.5-51mCi/ML) [RLD]
Is there a generic version of Amyvid available?
No. There is currently no therapeutically equivalent version of Amyvid available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Amyvid. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
Patent 7,687,052
Issued: March 30, 2010
Inventor(s): Kung; Hank F. et al.
Assignee(s): The Trustees of the University of Pennsylvania (Philadelphia, PA)This invention relates to a method of imaging amyloid deposits and to styrylpyridine compounds, and methods of making radiolabeled styrylpyridine compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.
Patent expiration dates:
- April 30, 2027✓✓
- April 30, 2027
-
Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
Patent 8,506,929
Issued: August 13, 2013
Inventor(s): Kung Hank F. & Kung Mei-Ping
Assignee(s): The Trustees of the University of PennsylvaniaThis invention relates to a method of imaging amyloid deposits and to styrylpyridine compounds, and methods of making radiolabeled styrylpyridine compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.
Patent expiration dates:
- April 30, 2027✓✓✓
- April 30, 2027
More about Amyvid (florbetapir F 18)
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: diagnostic radiopharmaceuticals
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.